Laurus Labs among 7 midcap stocks that hit 52-week highs and rallied up to 20% in a month
Seven BSE 150 MidCap stocks scaled fresh 52-week highs as Sensex surged 776 points in a broad-based rally. Lloyds Metals & Energy, Laurus Labs and Gujarat Fluorochemicals led the list, reflecting strong buying interest, positive momentum and improving investor confidence.
Explained: Why crude oil prices tumbled over 9% to below $90/bbl in one day
Crude oil prices plunged more than 9% to $88 a barrel after the US paused strikes on Iran and Tehran signalled restraint, boosting hopes of de-escalation. Reports said China is backing Pakistan’s efforts to revive US-Iran peace talks, easing fears of prolonged supply disruptions. The sharp decline in oil prices provided significant relief to global […]
Tata Chemicals Q1 Results: Profit plunges 81% to Rs 60 crore on higher expenses
Tata Chemicals experienced a significant eighty-one percent drop in profits for the June quarter, primarily due to increased expenses that affected its consolidated net profit. Despite this decline, the total income surged to Rs 4,311 crore, showing improvement compared to the same period last year. As a major player in the industrial and chemical sectors, […]
Canara Bank targets up to $2.5 billion via FCNR-B, overseas borrowings
Canara Bank plans to raise up to $2.5 billion through FCNR-B deposits and overseas borrowings to boost dollar inflows. The lender reported a 2.2% rise in first-quarter profit, improved asset quality, steady margins and double-digit growth in advances and deposits.
Indo-MIM IPO closes with over 72x subscription on Day 3, QIB portion booked 204x; GMP at 39%
Indo-MIM’s Rs 3,811.21 crore IPO received strong investor response on the final day of bidding. The shares are also trading at a grey market premium of around Rs 190, indicating a potential 39% listing gain over the upper price band, boosting investor interest ahead of the IPO closure.
Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth
Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.
Sterlite Tech shares jump 5% after CLSA upgrades 2026 multibagger after strong Q1 results
Sterlite Technologies shares surged after CLSA upgraded the stock to ‘Outperform’ and set a target price of Rs 950, implying a potential upside of 68%. The Vedanta-backed company has delivered a stellar run in 2026, with its stock rallying 466% so far this year, making it one of the biggest wealth creators in the market.
Tata Consumer shares jump 3% after Q1 results. Here’s why Nomura, Motilal see strong upside potential
Tata Consumer Products shares rose 3% after the FMCG major reported a 27.8% YoY jump in Q1 FY27 net profit to Rs 427 crore, while revenue increased 11.9% to Rs 5,349 crore. Brokerages remain bullish, with Nomura reiterating a Buy rating and raising its target price to Rs 1,475, citing calibrated price hikes, margin resilience […]
Bank of Baroda shares fall 2% after Q1 earnings. Why are brokerages slashing target prices?
Bank of Baroda shares fell after a sharp 72% drop in Q1 net profit due to a one-off NMC Health settlement. Brokerages cut target prices despite stable core performance. Margins, fee income and upcoming ECL norms remain key concerns, though asset quality and loan growth trends offer some support.
Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?
Dr Lal Path Labs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments.